Nicholas K. Email & Phone Number

Cambridge, England, GB

Led chemistry efforts on multiple immuno-oncology programs, leveraging Bicycle technology to design and develop potent, selective agonists. Optimized compounds through non-natural amino acid substitution, achieving sub-nanomolar KD values with favorable pharmacokinetic properties. Created targeted agonists for homo-multimeric and heterodimeric receptors.

Cambridge, MA, US

Drove synthesis and development of phosphorodiamidate morpholino oligomers (PMOs) to enhance intracellular delivery and modify biological activity. Led program development of non-viral delivery approaches, involving solid-phase synthesis, peptide conjugation, and novel moiety design. Coordinated in vivo/in vitro studies to test and iterate on these novel.

Cambridge, MA, US

Contributed to the development and optimization of oligonucleotide therapeutics for rare diseases. Conducted solid-phase synthesis and modulation of PMOs, designed modifications to optimize delivery and nuclear localization. Utilized various analytical techniques, including Isothermal Titration Calorimetry, to assess binding affinities and conjugation.

Brentford, Middlesex, GB

Designed, synthesized, purified, and analyzed small molecules selectively targeting kinases to control immune system response. Focused on modulating pharmacokinetic properties while identifying SAR trends contributing to selectivity, permeability, stability, and potency in biochemical & cellular binding assays. Leveraged crystallographic data, molecular.

US

Spinal Muscular Atrophy is the leading cause of genetic infant mortality and is characterized by the degeneration of motor neurons. One target for therapy involves up-regulation of the survival motor neuron (SMN) protein by increasing the amount of SMN2 mRNA. To achieve this, a library of small molecules has been designed and synthesized based on a.

Boston, MA, US

A novel approach to the production of heterocycles has been developed. Continuous flow microreactor technology was utilized to beget azides in situ and thereupon react them with cyanoacetamide in a [3+2] cycloaddition in order to yield a library of practical triazole components. Given concerns about the use of organic azides in macroscale synthesis, flow.

Rahway, New Jersey, US

An approach to protecting primary amines was developed through introduction of pyrroles via Paal-Knorr synthesis. The primary amines were cyclized with 1,4-diketones to produce pyrroles of varying substitution, acting as unique protective groups at isolated yields above 97%. These pyrroles showed unique properties as a protecting group to that of a.

Cambridge, MA, US

Methods to synthesis of a lead oncology compound were developed utilizing meso-scale continuous flow technology optimized to allow reagent and cost efficiency. This methodology allowed for unique control of kinetics and temperature in a scalable, reproducible manner. Alongside this project, novel methods of sulfamoyl substitution were performed on small.

Basel, Baselstadt, CH

Macular degeneration is a disease common in older adults, affecting the retina where the focus of treatment has been in inhibiting an enzyme believed to be involved in the disease. To achieve this inhibition, a variety of substitutions on the phenyl ring of a lead compound was explored. These substitutions altered several characteristics of the molecule.

Master Of Science (M.S.), Chemistry

Bachelor Of Science (B.S.), Chemistry

Education record